Technological innovation and changes to regulation are disrupting the hearing health sector, with implications for data privacy, product safety and accessibility, and provide challenges and opportunities for equitable hearing health.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A qualitative reflexive thematic analysis of innovation and regulation in hearing health care
BMC Medicine Open Access 27 September 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
WHO. https://go.nature.com/3TxrVqv (2021).
Nieman, C. L. et al. J. Aging Health 28, 68–94 (2016).
Lee, L. https://go.nature.com/3N3rGkU (2019).
Hunn, N. http://bit.ly/hearables2025 (2020).
FDA. 87 FR 50698; https://go.nature.com/3z6C7yk (2022).
Zuboff, S. The Age of Surveillance Capitalism: the Fight for a Human Future at the New Frontier of Power (Public Affairs, 2019).
Prainsack, B. & Forgó, N. Nat. Med. https://doi.org/10.1038/s41591-022-01955-4 (2022).
Coiera, E. et al. J. Am. Med. Inform. Assoc. 28, 1815–1825 (2021).
Crum, P. https://go.nature.com/3spEcBK (2019).
Pontoppidan, N. H. et al. US Patent 20140369537A1; https://go.nature.com/3SqFKpn (2014).
Ng, S. L. et al. Int. J. Audiol. 58, 576–586 (2019).
Sininger, Y. et al. Audiology Today 15, 14–17 (2003).
Liang, B. A. Semin. Hear. 27, 48–56 (2006).
McMahon, C. M. et al. Public Health Res. Pract. 31, e3152128 (2021).
Dawes, P. et al. Int. J. Audiol. 52, 472–477 (2013).
Coolen, J. et al. Can. J. Speech Lang. Pathol. Audiol. 36, 94–105 (2012).
Yong, M. et al. Bull. World Health Organ. 97, 699–710 (2019).
Fournier, P. Hear. Rev. 24, 26–28 (2017).
ACCC. https://go.nature.com/3MZByMd (2017).
Reed, N. S. et al. J. Am. Med. Assoc. 320, 1641–1642 (2018).
Humes, L. E. et al. Am. J. Audiol. 26, 53–79 (2017).
Martinez-Martin, N. et al. Lancet Digit. Health 3, e115–e123 (2020).
Blustein, J. et al. JAMA Otolaryngol. Head Neck Surg. 146, 765–766 (2020).
Shukla, A. et al. Am. J. Med. Qual. 34, 284–292 (2019).
Arcaya, M. C. et al. Health Aff. (Millwood) 36, 992–998 (2017).
Hsu, A. K. et al. Geriatr. Nurs. 40, 367–379 (2019).
Author information
Authors and Affiliations
Contributions
I.B., A.D., E.L., J.S.M. and W.L. conceived and developed the main ideas for this article. I.B. led the writing with substantial contributions from A.D., E.L. and M.C. All authors provided critical input, and approved the final version. M.N. provided a critical review from the perspective of a person with lived experience of hearing loss.
Corresponding author
Ethics declarations
Competing interests
I.B. is a collaborator on projects that receive funding from Cochlear, but maintains academic independence for all research initiatives. S.E.H. receives funding from the NIHR Blood and Transplant Research Unit (BTRU) in Precision Therapeutics, UKRI, National Technical Institute for the Deaf (NTID) COVID-19 Relief Fund, UK SPINE and declares personal fees from Cochlear, Astra Zeneca, CIS Oncolog, and Aparito outside the submitted work. M.C. receives funding from the National Institute for Health and Care Research (NIHR), UK Research and Innovation (UKRI), NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR Applied Research Collaboration (ARC) West Midlands, the NIHR Blood and Transplant Research Unit (BTRU) in Precision Therapeutics, UK SPINE, European Regional Development Fund – Demand Hub and Health Data Research UK at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB Pharma, Janssen, GSK and Gilead. M.C. has received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work; and a family member owns shares in GSK. The other authors declare having no relevant competing interests. The views expressed in this article are those of the authors and not necessarily those of their employing institutions.
Rights and permissions
About this article
Cite this article
Boisvert, I., Dunn, A.G., Lundmark, E. et al. Disruptions to the hearing health sector. Nat Med 29, 19–21 (2023). https://doi.org/10.1038/s41591-022-02086-6
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-022-02086-6